Humoral and T-cell immune responses to coronavirus disease 2019 vaccines in patients with hematological malignancies
This study provides confirmatory real-world evidence that CD19 recovery is a key determinant of humoral response, while vaccine-induced T-cell immunity may be preserved even in antibody-nonresponders, supporting continued vaccination efforts in this high-risk population.
Authors
- Shigehiro Yagishita (ORCID: https://orcid.org/0000-0002-1277-1203)
- NOBORU YAMAMOTO
- Koji Izutsu (ORCID: https://orcid.org/0000-0001-9129-8057)
- Noriko Iwaki
- Mika Shiotsuka (ORCID: https://orcid.org/0000-0003-1219-8387)
- Keiji Okinaka
- Masatoshi Yanagida (ORCID: https://orcid.org/0000-0002-4407-8120)
- Yuki Katsuya (ORCID: https://orcid.org/0000-0002-2127-3601)
- Shinichi Makita
- Wataru Munakata
- Akinobu Hamada
- Maki Shibata
- Yasushi Goto
- Hirokazu Sasaki
- Yasuhiro Irino
- Daiki Hattori
- Suguru Fukuhara
- Haruhi Makino
- Osamu Kobayashi
Institutions
- Jikei University School of Medicine (JP)
- National Cancer Centre Japan (JP)
- National Cancer Center (US)
- Sysmex (Japan) (JP)
- National Cancer Research Institute (GB)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1093/jjco/hyaf207
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00